nodes	percent_of_prediction	percent_of_DWPC	metapath
Methysergide—HTR2A—phrenic nerve—lung cancer	0.0393	0.318	CbGeAlD
Methysergide—HTR7—pulmonary artery—lung cancer	0.0229	0.185	CbGeAlD
Methysergide—HTR2A—pulmonary artery—lung cancer	0.0143	0.116	CbGeAlD
Methysergide—SIGMAR1—mammary gland—lung cancer	0.00676	0.0547	CbGeAlD
Methysergide—HTR7—respiratory system—lung cancer	0.00385	0.0312	CbGeAlD
Methysergide—SIGMAR1—bronchus—lung cancer	0.00371	0.03	CbGeAlD
Methysergide—SIGMAR1—trachea—lung cancer	0.00333	0.027	CbGeAlD
Methysergide—HTR7—epithelium—lung cancer	0.00322	0.026	CbGeAlD
Methysergide—SIGMAR1—cardiac atrium—lung cancer	0.00313	0.0253	CbGeAlD
Methysergide—HTR7—trachea—lung cancer	0.00285	0.023	CbGeAlD
Methysergide—SIGMAR1—bone marrow—lung cancer	0.00264	0.0214	CbGeAlD
Methysergide—HTR2A—respiratory system—lung cancer	0.0024	0.0194	CbGeAlD
Methysergide—SIGMAR1—lung—lung cancer	0.00239	0.0194	CbGeAlD
Methysergide—HTR2B—lung—lung cancer	0.00239	0.0193	CbGeAlD
Methysergide—HTR7—lung—lung cancer	0.00204	0.0166	CbGeAlD
Methysergide—HTR2A—epithelium—lung cancer	0.00201	0.0162	CbGeAlD
Methysergide—HTR2A—trachea—lung cancer	0.00177	0.0144	CbGeAlD
Methysergide—SIGMAR1—lymph node—lung cancer	0.00164	0.0132	CbGeAlD
Methysergide—HTR2B—lymph node—lung cancer	0.00163	0.0132	CbGeAlD
Methysergide—HTR2A—lung—lung cancer	0.00128	0.0103	CbGeAlD
Methysergide—Oedema—Gemcitabine—lung cancer	0.00104	0.0016	CcSEcCtD
Methysergide—Diarrhoea—Topotecan—lung cancer	0.00104	0.00159	CcSEcCtD
Methysergide—Back pain—Paclitaxel—lung cancer	0.00104	0.00159	CcSEcCtD
Methysergide—Dizziness—Vinblastine—lung cancer	0.00103	0.00159	CcSEcCtD
Methysergide—Convulsion—Cisplatin—lung cancer	0.00103	0.00158	CcSEcCtD
Methysergide—Diarrhoea—Erlotinib—lung cancer	0.00103	0.00158	CcSEcCtD
Methysergide—Abdominal pain—Vinorelbine—lung cancer	0.00103	0.00157	CcSEcCtD
Methysergide—Body temperature increased—Vinorelbine—lung cancer	0.00103	0.00157	CcSEcCtD
Methysergide—Oedema peripheral—Docetaxel—lung cancer	0.00103	0.00157	CcSEcCtD
Methysergide—Thrombocytopenia—Gemcitabine—lung cancer	0.00102	0.00157	CcSEcCtD
Methysergide—Ataxia—Methotrexate—lung cancer	0.00102	0.00157	CcSEcCtD
Methysergide—Myalgia—Cisplatin—lung cancer	0.00101	0.00156	CcSEcCtD
Methysergide—Ill-defined disorder—Etoposide—lung cancer	0.00101	0.00155	CcSEcCtD
Methysergide—Dizziness—Topotecan—lung cancer	0.001	0.00154	CcSEcCtD
Methysergide—Discomfort—Cisplatin—lung cancer	0.001	0.00154	CcSEcCtD
Methysergide—Vomiting—Vinblastine—lung cancer	0.000994	0.00152	CcSEcCtD
Methysergide—Dizziness—Erlotinib—lung cancer	0.000994	0.00152	CcSEcCtD
Methysergide—Ill-defined disorder—Paclitaxel—lung cancer	0.000994	0.00152	CcSEcCtD
Methysergide—Malaise—Etoposide—lung cancer	0.000985	0.00151	CcSEcCtD
Methysergide—Oedema—Cisplatin—lung cancer	0.000973	0.00149	CcSEcCtD
Methysergide—Insomnia—Irinotecan—lung cancer	0.000969	0.00149	CcSEcCtD
Methysergide—Flushing—Docetaxel—lung cancer	0.000968	0.00148	CcSEcCtD
Methysergide—Vomiting—Topotecan—lung cancer	0.000966	0.00148	CcSEcCtD
Methysergide—Malaise—Paclitaxel—lung cancer	0.000966	0.00148	CcSEcCtD
Methysergide—Paraesthesia—Irinotecan—lung cancer	0.000962	0.00148	CcSEcCtD
Methysergide—Rash—Topotecan—lung cancer	0.000958	0.00147	CcSEcCtD
Methysergide—Dermatitis—Topotecan—lung cancer	0.000957	0.00147	CcSEcCtD
Methysergide—Vomiting—Erlotinib—lung cancer	0.000955	0.00146	CcSEcCtD
Methysergide—Dyspnoea—Irinotecan—lung cancer	0.000955	0.00146	CcSEcCtD
Methysergide—Somnolence—Irinotecan—lung cancer	0.000953	0.00146	CcSEcCtD
Methysergide—Thrombocytopenia—Cisplatin—lung cancer	0.000953	0.00146	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Gemcitabine—lung cancer	0.000951	0.00146	CcSEcCtD
Methysergide—Tachycardia—Cisplatin—lung cancer	0.00095	0.00146	CcSEcCtD
Methysergide—Rash—Erlotinib—lung cancer	0.000948	0.00145	CcSEcCtD
Methysergide—Dermatitis—Erlotinib—lung cancer	0.000947	0.00145	CcSEcCtD
Methysergide—Convulsion—Etoposide—lung cancer	0.000946	0.00145	CcSEcCtD
Methysergide—Insomnia—Gemcitabine—lung cancer	0.000944	0.00145	CcSEcCtD
Methysergide—Dyspepsia—Irinotecan—lung cancer	0.000943	0.00145	CcSEcCtD
Methysergide—Pain in extremity—Doxorubicin—lung cancer	0.000941	0.00144	CcSEcCtD
Methysergide—Paraesthesia—Gemcitabine—lung cancer	0.000937	0.00144	CcSEcCtD
Methysergide—Asthenia—Vinorelbine—lung cancer	0.000932	0.00143	CcSEcCtD
Methysergide—Dyspnoea—Gemcitabine—lung cancer	0.000931	0.00143	CcSEcCtD
Methysergide—Chest pain—Etoposide—lung cancer	0.00093	0.00143	CcSEcCtD
Methysergide—Eosinophilia—Methotrexate—lung cancer	0.00093	0.00143	CcSEcCtD
Methysergide—Nausea—Vinblastine—lung cancer	0.000929	0.00142	CcSEcCtD
Methysergide—Somnolence—Gemcitabine—lung cancer	0.000928	0.00142	CcSEcCtD
Methysergide—Convulsion—Paclitaxel—lung cancer	0.000928	0.00142	CcSEcCtD
Methysergide—Gastrointestinal disorder—Irinotecan—lung cancer	0.000925	0.00142	CcSEcCtD
Methysergide—Fatigue—Irinotecan—lung cancer	0.000924	0.00142	CcSEcCtD
Methysergide—Alopecia—Docetaxel—lung cancer	0.000921	0.00141	CcSEcCtD
Methysergide—Discomfort—Etoposide—lung cancer	0.000919	0.00141	CcSEcCtD
Methysergide—Pain—Irinotecan—lung cancer	0.000916	0.0014	CcSEcCtD
Methysergide—Constipation—Irinotecan—lung cancer	0.000916	0.0014	CcSEcCtD
Methysergide—Myalgia—Paclitaxel—lung cancer	0.000912	0.0014	CcSEcCtD
Methysergide—Chest pain—Paclitaxel—lung cancer	0.000912	0.0014	CcSEcCtD
Methysergide—Arthralgia—Paclitaxel—lung cancer	0.000912	0.0014	CcSEcCtD
Methysergide—Nausea—Topotecan—lung cancer	0.000902	0.00138	CcSEcCtD
Methysergide—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000901	0.00138	CcSEcCtD
Methysergide—Discomfort—Paclitaxel—lung cancer	0.000901	0.00138	CcSEcCtD
Methysergide—Fatigue—Gemcitabine—lung cancer	0.0009	0.00138	CcSEcCtD
Methysergide—Pain—Gemcitabine—lung cancer	0.000893	0.00137	CcSEcCtD
Methysergide—Constipation—Gemcitabine—lung cancer	0.000893	0.00137	CcSEcCtD
Methysergide—Nausea—Erlotinib—lung cancer	0.000893	0.00137	CcSEcCtD
Methysergide—Diarrhoea—Vinorelbine—lung cancer	0.000889	0.00136	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000886	0.00136	CcSEcCtD
Methysergide—Ataxia—Doxorubicin—lung cancer	0.000884	0.00136	CcSEcCtD
Methysergide—Feeling abnormal—Irinotecan—lung cancer	0.000883	0.00135	CcSEcCtD
Methysergide—Back pain—Docetaxel—lung cancer	0.000878	0.00135	CcSEcCtD
Methysergide—Neutropenia—Methotrexate—lung cancer	0.000878	0.00135	CcSEcCtD
Methysergide—Dysuria—Methotrexate—lung cancer	0.000878	0.00135	CcSEcCtD
Methysergide—Gastrointestinal pain—Irinotecan—lung cancer	0.000876	0.00134	CcSEcCtD
Methysergide—Oedema—Paclitaxel—lung cancer	0.000874	0.00134	CcSEcCtD
Methysergide—Paraesthesia—Cisplatin—lung cancer	0.000874	0.00134	CcSEcCtD
Methysergide—Thrombocytopenia—Etoposide—lung cancer	0.000873	0.00134	CcSEcCtD
Methysergide—Tachycardia—Etoposide—lung cancer	0.00087	0.00133	CcSEcCtD
Methysergide—Dyspnoea—Cisplatin—lung cancer	0.000867	0.00133	CcSEcCtD
Methysergide—Ergonovine—ABCB1—lung cancer	0.000867	0.475	CrCbGaD
Methysergide—Feeling abnormal—Gemcitabine—lung cancer	0.00086	0.00132	CcSEcCtD
Methysergide—Dizziness—Vinorelbine—lung cancer	0.000859	0.00132	CcSEcCtD
Methysergide—Orthostatic hypotension—Doxorubicin—lung cancer	0.000859	0.00132	CcSEcCtD
Methysergide—Thrombocytopenia—Paclitaxel—lung cancer	0.000856	0.00131	CcSEcCtD
Methysergide—Tachycardia—Paclitaxel—lung cancer	0.000853	0.00131	CcSEcCtD
Methysergide—Abdominal pain—Irinotecan—lung cancer	0.000847	0.0013	CcSEcCtD
Methysergide—Body temperature increased—Irinotecan—lung cancer	0.000847	0.0013	CcSEcCtD
Methysergide—Gastrointestinal disorder—Cisplatin—lung cancer	0.00084	0.00129	CcSEcCtD
Methysergide—Drowsiness—Methotrexate—lung cancer	0.000837	0.00128	CcSEcCtD
Methysergide—Pain—Cisplatin—lung cancer	0.000832	0.00128	CcSEcCtD
Methysergide—Vomiting—Vinorelbine—lung cancer	0.000826	0.00127	CcSEcCtD
Methysergide—Body temperature increased—Gemcitabine—lung cancer	0.000825	0.00127	CcSEcCtD
Methysergide—Rash—Vinorelbine—lung cancer	0.000819	0.00126	CcSEcCtD
Methysergide—Dermatitis—Vinorelbine—lung cancer	0.000818	0.00125	CcSEcCtD
Methysergide—Eosinophilia—Doxorubicin—lung cancer	0.000805	0.00123	CcSEcCtD
Methysergide—Feeling abnormal—Cisplatin—lung cancer	0.000802	0.00123	CcSEcCtD
Methysergide—Paraesthesia—Etoposide—lung cancer	0.0008	0.00123	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000796	0.00122	CcSEcCtD
Methysergide—Dyspnoea—Etoposide—lung cancer	0.000795	0.00122	CcSEcCtD
Methysergide—Somnolence—Etoposide—lung cancer	0.000792	0.00121	CcSEcCtD
Methysergide—Insomnia—Paclitaxel—lung cancer	0.00079	0.00121	CcSEcCtD
Methysergide—Convulsion—Docetaxel—lung cancer	0.000786	0.00121	CcSEcCtD
Methysergide—Paraesthesia—Paclitaxel—lung cancer	0.000785	0.0012	CcSEcCtD
Methysergide—Dyspnoea—Paclitaxel—lung cancer	0.000779	0.00119	CcSEcCtD
Methysergide—Somnolence—Paclitaxel—lung cancer	0.000777	0.00119	CcSEcCtD
Methysergide—Chest pain—Docetaxel—lung cancer	0.000773	0.00118	CcSEcCtD
Methysergide—Arthralgia—Docetaxel—lung cancer	0.000773	0.00118	CcSEcCtD
Methysergide—Myalgia—Docetaxel—lung cancer	0.000773	0.00118	CcSEcCtD
Methysergide—Nausea—Vinorelbine—lung cancer	0.000772	0.00118	CcSEcCtD
Methysergide—Gastrointestinal disorder—Etoposide—lung cancer	0.00077	0.00118	CcSEcCtD
Methysergide—Dyspepsia—Paclitaxel—lung cancer	0.000769	0.00118	CcSEcCtD
Methysergide—Body temperature increased—Cisplatin—lung cancer	0.000769	0.00118	CcSEcCtD
Methysergide—Asthenia—Irinotecan—lung cancer	0.000769	0.00118	CcSEcCtD
Methysergide—Fatigue—Etoposide—lung cancer	0.000768	0.00118	CcSEcCtD
Methysergide—Pain—Etoposide—lung cancer	0.000762	0.00117	CcSEcCtD
Methysergide—Constipation—Etoposide—lung cancer	0.000762	0.00117	CcSEcCtD
Methysergide—Dysuria—Doxorubicin—lung cancer	0.00076	0.00117	CcSEcCtD
Methysergide—Neutropenia—Doxorubicin—lung cancer	0.00076	0.00117	CcSEcCtD
Methysergide—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000754	0.00116	CcSEcCtD
Methysergide—Fatigue—Paclitaxel—lung cancer	0.000753	0.00116	CcSEcCtD
Methysergide—Asthenia—Gemcitabine—lung cancer	0.000749	0.00115	CcSEcCtD
Methysergide—Pain—Paclitaxel—lung cancer	0.000747	0.00115	CcSEcCtD
Methysergide—Constipation—Paclitaxel—lung cancer	0.000747	0.00115	CcSEcCtD
Methysergide—Oedema—Docetaxel—lung cancer	0.000741	0.00114	CcSEcCtD
Methysergide—Weight increased—Doxorubicin—lung cancer	0.00074	0.00113	CcSEcCtD
Methysergide—Weight decreased—Doxorubicin—lung cancer	0.000735	0.00113	CcSEcCtD
Methysergide—Feeling abnormal—Etoposide—lung cancer	0.000735	0.00113	CcSEcCtD
Methysergide—Diarrhoea—Irinotecan—lung cancer	0.000733	0.00112	CcSEcCtD
Methysergide—Gastrointestinal pain—Etoposide—lung cancer	0.000729	0.00112	CcSEcCtD
Methysergide—Thrombocytopenia—Docetaxel—lung cancer	0.000725	0.00111	CcSEcCtD
Methysergide—Drowsiness—Doxorubicin—lung cancer	0.000725	0.00111	CcSEcCtD
Methysergide—Tachycardia—Docetaxel—lung cancer	0.000723	0.00111	CcSEcCtD
Methysergide—Feeling abnormal—Paclitaxel—lung cancer	0.00072	0.0011	CcSEcCtD
Methysergide—Gastrointestinal pain—Paclitaxel—lung cancer	0.000715	0.0011	CcSEcCtD
Methysergide—Diarrhoea—Gemcitabine—lung cancer	0.000714	0.0011	CcSEcCtD
Methysergide—Dizziness—Irinotecan—lung cancer	0.000709	0.00109	CcSEcCtD
Methysergide—Body temperature increased—Etoposide—lung cancer	0.000705	0.00108	CcSEcCtD
Methysergide—Abdominal pain—Etoposide—lung cancer	0.000705	0.00108	CcSEcCtD
Methysergide—Asthenia—Cisplatin—lung cancer	0.000698	0.00107	CcSEcCtD
Methysergide—Abdominal pain—Paclitaxel—lung cancer	0.000691	0.00106	CcSEcCtD
Methysergide—Body temperature increased—Paclitaxel—lung cancer	0.000691	0.00106	CcSEcCtD
Methysergide—Vomiting—Irinotecan—lung cancer	0.000681	0.00104	CcSEcCtD
Methysergide—Rash—Irinotecan—lung cancer	0.000676	0.00104	CcSEcCtD
Methysergide—Dermatitis—Irinotecan—lung cancer	0.000675	0.00103	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000675	0.00103	CcSEcCtD
Methysergide—Insomnia—Docetaxel—lung cancer	0.00067	0.00103	CcSEcCtD
Methysergide—Diarrhoea—Cisplatin—lung cancer	0.000666	0.00102	CcSEcCtD
Methysergide—Paraesthesia—Docetaxel—lung cancer	0.000665	0.00102	CcSEcCtD
Methysergide—Alopecia—Methotrexate—lung cancer	0.000664	0.00102	CcSEcCtD
Methysergide—Vomiting—Gemcitabine—lung cancer	0.000664	0.00102	CcSEcCtD
Methysergide—Dyspnoea—Docetaxel—lung cancer	0.00066	0.00101	CcSEcCtD
Methysergide—Somnolence—Docetaxel—lung cancer	0.000659	0.00101	CcSEcCtD
Methysergide—Rash—Gemcitabine—lung cancer	0.000658	0.00101	CcSEcCtD
Methysergide—Dermatitis—Gemcitabine—lung cancer	0.000658	0.00101	CcSEcCtD
Methysergide—Dyspepsia—Docetaxel—lung cancer	0.000652	0.001	CcSEcCtD
Methysergide—Oedema peripheral—Doxorubicin—lung cancer	0.000641	0.000983	CcSEcCtD
Methysergide—Gastrointestinal disorder—Docetaxel—lung cancer	0.00064	0.000981	CcSEcCtD
Methysergide—Asthenia—Etoposide—lung cancer	0.00064	0.000981	CcSEcCtD
Methysergide—Fatigue—Docetaxel—lung cancer	0.000639	0.000979	CcSEcCtD
Methysergide—Nausea—Irinotecan—lung cancer	0.000636	0.000976	CcSEcCtD
Methysergide—Pain—Docetaxel—lung cancer	0.000633	0.000971	CcSEcCtD
Methysergide—Constipation—Docetaxel—lung cancer	0.000633	0.000971	CcSEcCtD
Methysergide—Back pain—Methotrexate—lung cancer	0.000633	0.00097	CcSEcCtD
Methysergide—Asthenia—Paclitaxel—lung cancer	0.000627	0.000961	CcSEcCtD
Methysergide—Nausea—Gemcitabine—lung cancer	0.00062	0.000951	CcSEcCtD
Methysergide—Vomiting—Cisplatin—lung cancer	0.000619	0.000948	CcSEcCtD
Methysergide—Rash—Cisplatin—lung cancer	0.000613	0.000941	CcSEcCtD
Methysergide—Dermatitis—Cisplatin—lung cancer	0.000613	0.00094	CcSEcCtD
Methysergide—Feeling abnormal—Docetaxel—lung cancer	0.00061	0.000936	CcSEcCtD
Methysergide—Diarrhoea—Etoposide—lung cancer	0.00061	0.000935	CcSEcCtD
Methysergide—Ill-defined disorder—Methotrexate—lung cancer	0.000607	0.000931	CcSEcCtD
Methysergide—Gastrointestinal pain—Docetaxel—lung cancer	0.000606	0.000929	CcSEcCtD
Methysergide—Flushing—Doxorubicin—lung cancer	0.000604	0.000926	CcSEcCtD
Methysergide—Diarrhoea—Paclitaxel—lung cancer	0.000598	0.000917	CcSEcCtD
Methysergide—Malaise—Methotrexate—lung cancer	0.00059	0.000904	CcSEcCtD
Methysergide—Dizziness—Etoposide—lung cancer	0.000589	0.000904	CcSEcCtD
Methysergide—Abdominal pain—Docetaxel—lung cancer	0.000586	0.000898	CcSEcCtD
Methysergide—Body temperature increased—Docetaxel—lung cancer	0.000586	0.000898	CcSEcCtD
Methysergide—Dizziness—Paclitaxel—lung cancer	0.000578	0.000886	CcSEcCtD
Methysergide—Nausea—Cisplatin—lung cancer	0.000578	0.000886	CcSEcCtD
Methysergide—Alopecia—Doxorubicin—lung cancer	0.000575	0.000882	CcSEcCtD
Methysergide—Convulsion—Methotrexate—lung cancer	0.000567	0.000869	CcSEcCtD
Methysergide—Vomiting—Etoposide—lung cancer	0.000567	0.000869	CcSEcCtD
Methysergide—Rash—Etoposide—lung cancer	0.000562	0.000862	CcSEcCtD
Methysergide—Dermatitis—Etoposide—lung cancer	0.000561	0.000861	CcSEcCtD
Methysergide—Myalgia—Methotrexate—lung cancer	0.000557	0.000854	CcSEcCtD
Methysergide—Chest pain—Methotrexate—lung cancer	0.000557	0.000854	CcSEcCtD
Methysergide—Arthralgia—Methotrexate—lung cancer	0.000557	0.000854	CcSEcCtD
Methysergide—Vomiting—Paclitaxel—lung cancer	0.000556	0.000852	CcSEcCtD
Methysergide—Rash—Paclitaxel—lung cancer	0.000551	0.000845	CcSEcCtD
Methysergide—Dermatitis—Paclitaxel—lung cancer	0.000551	0.000844	CcSEcCtD
Methysergide—Discomfort—Methotrexate—lung cancer	0.00055	0.000844	CcSEcCtD
Methysergide—Back pain—Doxorubicin—lung cancer	0.000548	0.00084	CcSEcCtD
Methysergide—Asthenia—Docetaxel—lung cancer	0.000531	0.000815	CcSEcCtD
Methysergide—Nausea—Etoposide—lung cancer	0.000529	0.000812	CcSEcCtD
Methysergide—Ill-defined disorder—Doxorubicin—lung cancer	0.000526	0.000806	CcSEcCtD
Methysergide—Thrombocytopenia—Methotrexate—lung cancer	0.000523	0.000801	CcSEcCtD
Methysergide—Nausea—Paclitaxel—lung cancer	0.000519	0.000796	CcSEcCtD
Methysergide—Malaise—Doxorubicin—lung cancer	0.000511	0.000783	CcSEcCtD
Methysergide—Diarrhoea—Docetaxel—lung cancer	0.000507	0.000777	CcSEcCtD
Methysergide—Convulsion—Doxorubicin—lung cancer	0.000491	0.000752	CcSEcCtD
Methysergide—Dizziness—Docetaxel—lung cancer	0.00049	0.000751	CcSEcCtD
Methysergide—Ergotamine—ABCB1—lung cancer	0.000488	0.267	CrCbGaD
Methysergide—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000486	0.000746	CcSEcCtD
Methysergide—Insomnia—Methotrexate—lung cancer	0.000483	0.00074	CcSEcCtD
Methysergide—Chest pain—Doxorubicin—lung cancer	0.000482	0.000739	CcSEcCtD
Methysergide—Arthralgia—Doxorubicin—lung cancer	0.000482	0.000739	CcSEcCtD
Methysergide—Myalgia—Doxorubicin—lung cancer	0.000482	0.000739	CcSEcCtD
Methysergide—Paraesthesia—Methotrexate—lung cancer	0.000479	0.000735	CcSEcCtD
Methysergide—Discomfort—Doxorubicin—lung cancer	0.000476	0.000731	CcSEcCtD
Methysergide—Dyspnoea—Methotrexate—lung cancer	0.000476	0.00073	CcSEcCtD
Methysergide—Somnolence—Methotrexate—lung cancer	0.000475	0.000728	CcSEcCtD
Methysergide—Vomiting—Docetaxel—lung cancer	0.000471	0.000722	CcSEcCtD
Methysergide—Bromocriptine—ABCB1—lung cancer	0.000471	0.258	CrCbGaD
Methysergide—Dyspepsia—Methotrexate—lung cancer	0.00047	0.000721	CcSEcCtD
Methysergide—Rash—Docetaxel—lung cancer	0.000467	0.000716	CcSEcCtD
Methysergide—Dermatitis—Docetaxel—lung cancer	0.000467	0.000715	CcSEcCtD
Methysergide—Oedema—Doxorubicin—lung cancer	0.000462	0.000709	CcSEcCtD
Methysergide—Gastrointestinal disorder—Methotrexate—lung cancer	0.000461	0.000707	CcSEcCtD
Methysergide—Fatigue—Methotrexate—lung cancer	0.00046	0.000706	CcSEcCtD
Methysergide—Pain—Methotrexate—lung cancer	0.000457	0.0007	CcSEcCtD
Methysergide—Thrombocytopenia—Doxorubicin—lung cancer	0.000453	0.000694	CcSEcCtD
Methysergide—Tachycardia—Doxorubicin—lung cancer	0.000451	0.000692	CcSEcCtD
Methysergide—Nausea—Docetaxel—lung cancer	0.00044	0.000675	CcSEcCtD
Methysergide—Feeling abnormal—Methotrexate—lung cancer	0.00044	0.000675	CcSEcCtD
Methysergide—Gastrointestinal pain—Methotrexate—lung cancer	0.000437	0.000669	CcSEcCtD
Methysergide—Abdominal pain—Methotrexate—lung cancer	0.000422	0.000647	CcSEcCtD
Methysergide—Body temperature increased—Methotrexate—lung cancer	0.000422	0.000647	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000421	0.000646	CcSEcCtD
Methysergide—Insomnia—Doxorubicin—lung cancer	0.000418	0.000641	CcSEcCtD
Methysergide—Paraesthesia—Doxorubicin—lung cancer	0.000415	0.000636	CcSEcCtD
Methysergide—Dyspnoea—Doxorubicin—lung cancer	0.000412	0.000632	CcSEcCtD
Methysergide—Somnolence—Doxorubicin—lung cancer	0.000411	0.00063	CcSEcCtD
Methysergide—Dyspepsia—Doxorubicin—lung cancer	0.000407	0.000624	CcSEcCtD
Methysergide—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000399	0.000612	CcSEcCtD
Methysergide—Fatigue—Doxorubicin—lung cancer	0.000399	0.000611	CcSEcCtD
Methysergide—Pain—Doxorubicin—lung cancer	0.000395	0.000606	CcSEcCtD
Methysergide—Constipation—Doxorubicin—lung cancer	0.000395	0.000606	CcSEcCtD
Methysergide—Asthenia—Methotrexate—lung cancer	0.000383	0.000587	CcSEcCtD
Methysergide—Feeling abnormal—Doxorubicin—lung cancer	0.000381	0.000584	CcSEcCtD
Methysergide—Gastrointestinal pain—Doxorubicin—lung cancer	0.000378	0.00058	CcSEcCtD
Methysergide—Abdominal pain—Doxorubicin—lung cancer	0.000365	0.00056	CcSEcCtD
Methysergide—Body temperature increased—Doxorubicin—lung cancer	0.000365	0.00056	CcSEcCtD
Methysergide—Diarrhoea—Methotrexate—lung cancer	0.000365	0.00056	CcSEcCtD
Methysergide—Dizziness—Methotrexate—lung cancer	0.000353	0.000541	CcSEcCtD
Methysergide—Vomiting—Methotrexate—lung cancer	0.000339	0.00052	CcSEcCtD
Methysergide—Rash—Methotrexate—lung cancer	0.000337	0.000516	CcSEcCtD
Methysergide—Dermatitis—Methotrexate—lung cancer	0.000336	0.000516	CcSEcCtD
Methysergide—Asthenia—Doxorubicin—lung cancer	0.000332	0.000509	CcSEcCtD
Methysergide—Nausea—Methotrexate—lung cancer	0.000317	0.000486	CcSEcCtD
Methysergide—Diarrhoea—Doxorubicin—lung cancer	0.000316	0.000485	CcSEcCtD
Methysergide—Dizziness—Doxorubicin—lung cancer	0.000306	0.000469	CcSEcCtD
Methysergide—Vomiting—Doxorubicin—lung cancer	0.000294	0.000451	CcSEcCtD
Methysergide—Rash—Doxorubicin—lung cancer	0.000291	0.000447	CcSEcCtD
Methysergide—Dermatitis—Doxorubicin—lung cancer	0.000291	0.000447	CcSEcCtD
Methysergide—Nausea—Doxorubicin—lung cancer	0.000275	0.000421	CcSEcCtD
Methysergide—HTR7—Signaling by GPCR—IL6—lung cancer	2.63e-05	0.000118	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CASP3—lung cancer	2.63e-05	0.000118	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—IL2—lung cancer	2.62e-05	0.000118	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—BRAF—lung cancer	2.62e-05	0.000118	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—IL6—lung cancer	2.61e-05	0.000117	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—KDR—lung cancer	2.61e-05	0.000117	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—BRAF—lung cancer	2.6e-05	0.000117	CbGpPWpGaD
Methysergide—HTR1B—GPCR downstream signaling—AKT1—lung cancer	2.6e-05	0.000117	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IL6R—lung cancer	2.58e-05	0.000116	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CREBBP—lung cancer	2.58e-05	0.000116	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CCND1—lung cancer	2.58e-05	0.000116	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CCND1—lung cancer	2.58e-05	0.000116	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CASP3—lung cancer	2.57e-05	0.000116	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—JUN—lung cancer	2.57e-05	0.000116	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—IL2—lung cancer	2.57e-05	0.000116	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—JUN—lung cancer	2.57e-05	0.000116	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—PIK3CA—lung cancer	2.57e-05	0.000116	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IL6R—lung cancer	2.57e-05	0.000116	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CREBBP—lung cancer	2.57e-05	0.000115	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CCND1—lung cancer	2.56e-05	0.000115	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—IL6—lung cancer	2.56e-05	0.000115	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—JUN—lung cancer	2.55e-05	0.000115	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—EGFR—lung cancer	2.53e-05	0.000114	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CXCL8—lung cancer	2.53e-05	0.000114	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—EGFR—lung cancer	2.52e-05	0.000113	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—HRAS—lung cancer	2.52e-05	0.000113	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—HRAS—lung cancer	2.51e-05	0.000113	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CCND1—lung cancer	2.51e-05	0.000113	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MMP9—lung cancer	2.5e-05	0.000113	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MMP9—lung cancer	2.5e-05	0.000112	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—JUN—lung cancer	2.5e-05	0.000112	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CDKN1A—lung cancer	2.49e-05	0.000112	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CDKN1A—lung cancer	2.49e-05	0.000112	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—PTEN—lung cancer	2.49e-05	0.000112	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—TP53—lung cancer	2.49e-05	0.000112	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—PTEN—lung cancer	2.49e-05	0.000112	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MMP9—lung cancer	2.48e-05	0.000112	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CDKN1A—lung cancer	2.48e-05	0.000111	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—PTEN—lung cancer	2.47e-05	0.000111	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MAP2K1—lung cancer	2.46e-05	0.000111	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MAP2K1—lung cancer	2.45e-05	0.00011	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3CD—lung cancer	2.45e-05	0.00011	CbGpPWpGaD
Methysergide—HTR2B—GPCR downstream signaling—AKT1—lung cancer	2.44e-05	0.00011	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3CD—lung cancer	2.43e-05	0.000109	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MMP9—lung cancer	2.43e-05	0.000109	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—AKT1—lung cancer	2.43e-05	0.000109	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—AKT1—lung cancer	2.43e-05	0.000109	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CDKN1A—lung cancer	2.42e-05	0.000109	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—PIK3CA—lung cancer	2.42e-05	0.000109	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—PTEN—lung cancer	2.42e-05	0.000109	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CASP3—lung cancer	2.42e-05	0.000109	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—IL2—lung cancer	2.41e-05	0.000109	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—IL6—lung cancer	2.41e-05	0.000108	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—PIK3CA—lung cancer	2.41e-05	0.000108	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—AKT1—lung cancer	2.41e-05	0.000108	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CG—lung cancer	2.4e-05	0.000108	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—APC—lung cancer	2.4e-05	0.000108	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—KIT—lung cancer	2.4e-05	0.000108	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—NRAS—lung cancer	2.4e-05	0.000108	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—IL6—lung cancer	2.4e-05	0.000108	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—KRAS—lung cancer	2.39e-05	0.000108	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—KRAS—lung cancer	2.38e-05	0.000107	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—HRAS—lung cancer	2.38e-05	0.000107	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—EGF—lung cancer	2.38e-05	0.000107	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—EP300—lung cancer	2.37e-05	0.000107	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—EP300—lung cancer	2.37e-05	0.000107	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—AKT1—lung cancer	2.36e-05	0.000106	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—EP300—lung cancer	2.36e-05	0.000106	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CCND1—lung cancer	2.35e-05	0.000106	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—JUN—lung cancer	2.35e-05	0.000106	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—SRC—lung cancer	2.31e-05	0.000104	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—EP300—lung cancer	2.31e-05	0.000104	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—SRC—lung cancer	2.31e-05	0.000104	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—MAPK3—lung cancer	2.3e-05	0.000103	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—SRC—lung cancer	2.29e-05	0.000103	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—POMC—lung cancer	2.29e-05	0.000103	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MMP9—lung cancer	2.29e-05	0.000103	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CDKN1A—lung cancer	2.28e-05	0.000102	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—IL6—lung cancer	2.28e-05	0.000102	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PTEN—lung cancer	2.27e-05	0.000102	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—BRAF—lung cancer	2.26e-05	0.000102	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—VEGFA—lung cancer	2.25e-05	0.000101	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—VEGFA—lung cancer	2.25e-05	0.000101	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—SRC—lung cancer	2.24e-05	0.000101	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IL6R—lung cancer	2.23e-05	0.0001	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—VEGFA—lung cancer	2.23e-05	0.0001	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CREBBP—lung cancer	2.23e-05	0.0001	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—AKT1—lung cancer	2.23e-05	0.0001	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—STAT3—lung cancer	2.23e-05	0.0001	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—STAT3—lung cancer	2.22e-05	0.0001	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—NRAS—lung cancer	2.22e-05	9.98e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—NRAS—lung cancer	2.22e-05	9.97e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—AKT1—lung cancer	2.22e-05	9.96e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—STAT3—lung cancer	2.21e-05	9.93e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—NRAS—lung cancer	2.2e-05	9.91e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—PIK3CA—lung cancer	2.2e-05	9.89e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MDM2—lung cancer	2.19e-05	9.85e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—EGFR—lung cancer	2.19e-05	9.85e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—PIK3CA—lung cancer	2.19e-05	9.84e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—VEGFA—lung cancer	2.18e-05	9.82e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—RAF1—lung cancer	2.18e-05	9.82e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MDM2—lung cancer	2.18e-05	9.8e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—RAF1—lung cancer	2.17e-05	9.77e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—EP300—lung cancer	2.17e-05	9.74e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—STAT3—lung cancer	2.16e-05	9.72e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—ERBB2—lung cancer	2.16e-05	9.71e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—NRAS—lung cancer	2.16e-05	9.7e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—ERBB2—lung cancer	2.15e-05	9.66e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MTOR—lung cancer	2.13e-05	9.59e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3CB—lung cancer	2.13e-05	9.59e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MAP2K1—lung cancer	2.13e-05	9.56e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MAPK3—lung cancer	2.13e-05	9.56e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MAPK3—lung cancer	2.12e-05	9.55e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MTOR—lung cancer	2.12e-05	9.54e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3CB—lung cancer	2.12e-05	9.54e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CD—lung cancer	2.11e-05	9.5e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MAPK3—lung cancer	2.11e-05	9.49e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—SRC—lung cancer	2.11e-05	9.47e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—AKT1—lung cancer	2.1e-05	9.44e-05	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—PIK3CA—lung cancer	2.09e-05	9.41e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—KRAS—lung cancer	2.07e-05	9.3e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MYC—lung cancer	2.07e-05	9.3e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MAPK3—lung cancer	2.07e-05	9.29e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MYC—lung cancer	2.07e-05	9.29e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MYC—lung cancer	2.05e-05	9.23e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—VEGFA—lung cancer	2.05e-05	9.23e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CXCL8—lung cancer	2.05e-05	9.21e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CXCL8—lung cancer	2.04e-05	9.16e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—HRAS—lung cancer	2.04e-05	9.15e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—STAT3—lung cancer	2.03e-05	9.13e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—NRAS—lung cancer	2.03e-05	9.11e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—HRAS—lung cancer	2.02e-05	9.1e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—EGFR—lung cancer	2.02e-05	9.1e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—EGFR—lung cancer	2.02e-05	9.09e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MYC—lung cancer	2.01e-05	9.04e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—EGFR—lung cancer	2.01e-05	9.03e-05	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—AKT1—lung cancer	1.98e-05	8.9e-05	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—AKT1—lung cancer	1.97e-05	8.85e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—EGFR—lung cancer	1.97e-05	8.84e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CASP3—lung cancer	1.96e-05	8.82e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IL2—lung cancer	1.96e-05	8.8e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CASP3—lung cancer	1.95e-05	8.77e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—IL6—lung cancer	1.95e-05	8.76e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IL2—lung cancer	1.95e-05	8.76e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MAPK3—lung cancer	1.94e-05	8.73e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—IL6—lung cancer	1.94e-05	8.71e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—KRAS—lung cancer	1.91e-05	8.59e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—KRAS—lung cancer	1.91e-05	8.58e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CCND1—lung cancer	1.91e-05	8.58e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—JUN—lung cancer	1.9e-05	8.56e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—PIK3CA—lung cancer	1.9e-05	8.55e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CCND1—lung cancer	1.9e-05	8.54e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—KRAS—lung cancer	1.9e-05	8.53e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—JUN—lung cancer	1.89e-05	8.52e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MDM2—lung cancer	1.89e-05	8.51e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MYC—lung cancer	1.89e-05	8.49e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—RAF1—lung cancer	1.89e-05	8.48e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—ERBB2—lung cancer	1.87e-05	8.39e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—KRAS—lung cancer	1.86e-05	8.35e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MMP9—lung cancer	1.85e-05	8.33e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—EGFR—lung cancer	1.85e-05	8.3e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CDKN1A—lung cancer	1.85e-05	8.3e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MMP9—lung cancer	1.84e-05	8.29e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PTEN—lung cancer	1.84e-05	8.28e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CB—lung cancer	1.84e-05	8.28e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MTOR—lung cancer	1.84e-05	8.28e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CDKN1A—lung cancer	1.84e-05	8.26e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PTEN—lung cancer	1.83e-05	8.24e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—AKT1—lung cancer	1.8e-05	8.08e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—AKT1—lung cancer	1.79e-05	8.04e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CXCL8—lung cancer	1.77e-05	7.96e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—HRAS—lung cancer	1.76e-05	7.91e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—EP300—lung cancer	1.76e-05	7.9e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—PIK3CA—lung cancer	1.76e-05	7.89e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—PIK3CA—lung cancer	1.75e-05	7.89e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—EP300—lung cancer	1.75e-05	7.86e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—KRAS—lung cancer	1.74e-05	7.84e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—PIK3CA—lung cancer	1.74e-05	7.83e-05	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—AKT1—lung cancer	1.71e-05	7.69e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—SRC—lung cancer	1.71e-05	7.68e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—PIK3CA—lung cancer	1.71e-05	7.67e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—SRC—lung cancer	1.7e-05	7.64e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—TP53—lung cancer	1.7e-05	7.64e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—TP53—lung cancer	1.7e-05	7.63e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CASP3—lung cancer	1.69e-05	7.62e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IL2—lung cancer	1.69e-05	7.6e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—TP53—lung cancer	1.69e-05	7.58e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—IL6—lung cancer	1.68e-05	7.57e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—VEGFA—lung cancer	1.66e-05	7.48e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—VEGFA—lung cancer	1.66e-05	7.44e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—TP53—lung cancer	1.65e-05	7.42e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CCND1—lung cancer	1.65e-05	7.41e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—STAT3—lung cancer	1.65e-05	7.41e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—JUN—lung cancer	1.65e-05	7.4e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—NRAS—lung cancer	1.64e-05	7.39e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—STAT3—lung cancer	1.64e-05	7.37e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—NRAS—lung cancer	1.64e-05	7.35e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—HRAS—lung cancer	1.62e-05	7.3e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—HRAS—lung cancer	1.62e-05	7.3e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—HRAS—lung cancer	1.61e-05	7.25e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PIK3CA—lung cancer	1.6e-05	7.21e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MMP9—lung cancer	1.6e-05	7.2e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CDKN1A—lung cancer	1.6e-05	7.17e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PTEN—lung cancer	1.59e-05	7.16e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—HRAS—lung cancer	1.58e-05	7.1e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MAPK3—lung cancer	1.57e-05	7.08e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MAPK3—lung cancer	1.57e-05	7.04e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—IL6—lung cancer	1.55e-05	6.99e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—IL6—lung cancer	1.55e-05	6.98e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—AKT1—lung cancer	1.55e-05	6.98e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—TP53—lung cancer	1.55e-05	6.97e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—IL6—lung cancer	1.54e-05	6.94e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MYC—lung cancer	1.53e-05	6.88e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MYC—lung cancer	1.52e-05	6.85e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—EP300—lung cancer	1.52e-05	6.82e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—IL6—lung cancer	1.51e-05	6.79e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—EGFR—lung cancer	1.5e-05	6.73e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—EGFR—lung cancer	1.49e-05	6.7e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—HRAS—lung cancer	1.48e-05	6.67e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—SRC—lung cancer	1.48e-05	6.64e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—VEGFA—lung cancer	1.44e-05	6.46e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—AKT1—lung cancer	1.43e-05	6.45e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—AKT1—lung cancer	1.43e-05	6.44e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—AKT1—lung cancer	1.42e-05	6.4e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—STAT3—lung cancer	1.42e-05	6.4e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—NRAS—lung cancer	1.42e-05	6.38e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—IL6—lung cancer	1.42e-05	6.38e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—KRAS—lung cancer	1.41e-05	6.36e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—KRAS—lung cancer	1.41e-05	6.33e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—AKT1—lung cancer	1.39e-05	6.27e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MAPK3—lung cancer	1.36e-05	6.11e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MYC—lung cancer	1.32e-05	5.95e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—AKT1—lung cancer	1.31e-05	5.89e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3CA—lung cancer	1.3e-05	5.84e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—EGFR—lung cancer	1.29e-05	5.82e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3CA—lung cancer	1.29e-05	5.81e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TP53—lung cancer	1.26e-05	5.65e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TP53—lung cancer	1.25e-05	5.62e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—KRAS—lung cancer	1.22e-05	5.49e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—HRAS—lung cancer	1.2e-05	5.41e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—HRAS—lung cancer	1.2e-05	5.38e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IL6—lung cancer	1.15e-05	5.17e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IL6—lung cancer	1.14e-05	5.15e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3CA—lung cancer	1.12e-05	5.05e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TP53—lung cancer	1.09e-05	4.88e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—AKT1—lung cancer	1.06e-05	4.77e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—AKT1—lung cancer	1.06e-05	4.75e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—HRAS—lung cancer	1.04e-05	4.67e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IL6—lung cancer	9.94e-06	4.47e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—AKT1—lung cancer	9.17e-06	4.12e-05	CbGpPWpGaD
